A Santa Cruz family received a fully adaptable van for their 12-year-old son with Duchenne muscular dystrophy, funded by ...
Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - ...
Gillette Children’s Specialty Healthcare in St. Paul was first to set up special program for providing still-experimental ...
Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare disease specialist, has received a positive opinion ...
The EMA has backed broader pediatric use of Agamree and Crysvita, lowering age thresholds for rare genetic diseases affecting muscle and bone development.
Santhera Pharmaceuticals (SIX: SANN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending ...
Oxford Mail on MSN
Oxfordshire barrister named campaigner of the year
An Oxfordshire barrister living with muscular dystrophy has been named Campaigner of the Year by the national charity ...
A Morris dancer from Hastings is hoping to break a world record when he runs Sunday's London Marathon - and he said he was ...
A disabled Twitch streamer known for beating difficult games with his chin has returned to the platform to beat Super Mario ...
Deramiocel is a novel cellular therapy that demonstrated benefit on skeletal muscle function in the HOPE-2 phase II study of ...
The FDA is signaling change, but actual success depends on more than simply bringing in a new leader at the Center for ...
Scientists sum up the evidence—or lack thereof—for the most popular peptides hyped for athletic performance and recovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results